Tech Company Financing Transactions
CXL Ophthalmics Funding Round
CXL Ophthalmics closed a $32 million Series A venture capital round on 10/1/2022. Investors included AXA Investment Managers and private investors.
Transaction Overview
Company Name
Announced On
10/1/2022
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series A
Investors
AXA Investment Managers (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the advancement of its cross-linking system, EpiSmart, through Phase 3 trials on the way to a New Drug Application with FDA.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
4354 Manchester Ave.
Encinitas, CA 92024
USA
Encinitas, CA 92024
USA
Phone
Undisclosed
Website
Email Address
Overview
CXLO is developing a minimally?invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally.?Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without?disrupting?the epithelium, allowing for a?rapid return to normal activities.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Webb
Chief Medical Officer
Michael Belin
Chief Operating Officer
Edward Parsons
VP - Bus. Development
Alan Russell
VP - R & D
Kevin Daly
Browse more venture capital transactions:
Prev: 9/30/2022: Klaus venture capital transaction
Next: 10/1/2022: Toragen venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs